Cargando…

Opioid use, regulation, and harms in Brazil: a comprehensive narrative overview of available data and indicators

BACKGROUND: Global opioid consumption increased multifold post-2000, disproportionately in high-income countries, with severe mortality/morbidity consequences. Latin America features comparatively low opioid availability; Brazil, the region’s most populous country, makes an interesting case study co...

Descripción completa

Detalles Bibliográficos
Autores principales: Maia, Lucas O., Daldegan-Bueno, Dimitri, Fischer, Benedikt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836143/
https://www.ncbi.nlm.nih.gov/pubmed/33499891
http://dx.doi.org/10.1186/s13011-021-00348-z
_version_ 1783642683407859712
author Maia, Lucas O.
Daldegan-Bueno, Dimitri
Fischer, Benedikt
author_facet Maia, Lucas O.
Daldegan-Bueno, Dimitri
Fischer, Benedikt
author_sort Maia, Lucas O.
collection PubMed
description BACKGROUND: Global opioid consumption increased multifold post-2000, disproportionately in high-income countries, with severe mortality/morbidity consequences. Latin America features comparatively low opioid availability; Brazil, the region’s most populous country, makes an interesting case study concerning opioid use/harms. In this comprehensive overview, we aimed to identify and summarize medical and non-medical data and indicators of opioid availability and use, regulation/control, and harm outcomes in Brazil since 2000. METHODS: We searched multiple scientific databases to identify relevant publications and conducted additional ‘grey’ literature searches to identify other pertinent information. RESULTS: Despite some essential indicators, opioid-related data are limited for Brazil. Data indicate that population-level availability of prescription opioids represents only a small fraction of use in comparison to high-income countries. However, within Latin America, Brazil ranks mid-level for opioid consumption, indicating relatively moderate consumption compared to neighboring jurisdictions. Brazil has implemented restrictive regulations to opioid prescribing and is considered ‘highly restricted’ for opioid access. Codeine remains the major opioid analgesic utilized, but stronger opioids such as oxycodone are becoming more common. Professional knowledge regarding medical opioid use and effects appears limited. National surveys indicate increases in non-medical use of prescription opioids, albeit lower than observed in North America, while illicit opioids (e.g., heroin) are highly uncommon. CONCLUSIONS: Overall population-level opioid availability and corresponding levels of opioid-related harms in Brazil remain substantially lower than rates reported for North America. However, the available surveillance and analytical data on opioid use, policy/practice, and harms in Brazil are limited and insufficient. Since existing and acute (e.g., pain-related) needs for improved opioid utilization and practice appear to be substantiated, improved indicators for and understanding of opioid use, practice, and harms in Brazil are required.
format Online
Article
Text
id pubmed-7836143
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-78361432021-01-26 Opioid use, regulation, and harms in Brazil: a comprehensive narrative overview of available data and indicators Maia, Lucas O. Daldegan-Bueno, Dimitri Fischer, Benedikt Subst Abuse Treat Prev Policy Review BACKGROUND: Global opioid consumption increased multifold post-2000, disproportionately in high-income countries, with severe mortality/morbidity consequences. Latin America features comparatively low opioid availability; Brazil, the region’s most populous country, makes an interesting case study concerning opioid use/harms. In this comprehensive overview, we aimed to identify and summarize medical and non-medical data and indicators of opioid availability and use, regulation/control, and harm outcomes in Brazil since 2000. METHODS: We searched multiple scientific databases to identify relevant publications and conducted additional ‘grey’ literature searches to identify other pertinent information. RESULTS: Despite some essential indicators, opioid-related data are limited for Brazil. Data indicate that population-level availability of prescription opioids represents only a small fraction of use in comparison to high-income countries. However, within Latin America, Brazil ranks mid-level for opioid consumption, indicating relatively moderate consumption compared to neighboring jurisdictions. Brazil has implemented restrictive regulations to opioid prescribing and is considered ‘highly restricted’ for opioid access. Codeine remains the major opioid analgesic utilized, but stronger opioids such as oxycodone are becoming more common. Professional knowledge regarding medical opioid use and effects appears limited. National surveys indicate increases in non-medical use of prescription opioids, albeit lower than observed in North America, while illicit opioids (e.g., heroin) are highly uncommon. CONCLUSIONS: Overall population-level opioid availability and corresponding levels of opioid-related harms in Brazil remain substantially lower than rates reported for North America. However, the available surveillance and analytical data on opioid use, policy/practice, and harms in Brazil are limited and insufficient. Since existing and acute (e.g., pain-related) needs for improved opioid utilization and practice appear to be substantiated, improved indicators for and understanding of opioid use, practice, and harms in Brazil are required. BioMed Central 2021-01-26 /pmc/articles/PMC7836143/ /pubmed/33499891 http://dx.doi.org/10.1186/s13011-021-00348-z Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Maia, Lucas O.
Daldegan-Bueno, Dimitri
Fischer, Benedikt
Opioid use, regulation, and harms in Brazil: a comprehensive narrative overview of available data and indicators
title Opioid use, regulation, and harms in Brazil: a comprehensive narrative overview of available data and indicators
title_full Opioid use, regulation, and harms in Brazil: a comprehensive narrative overview of available data and indicators
title_fullStr Opioid use, regulation, and harms in Brazil: a comprehensive narrative overview of available data and indicators
title_full_unstemmed Opioid use, regulation, and harms in Brazil: a comprehensive narrative overview of available data and indicators
title_short Opioid use, regulation, and harms in Brazil: a comprehensive narrative overview of available data and indicators
title_sort opioid use, regulation, and harms in brazil: a comprehensive narrative overview of available data and indicators
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836143/
https://www.ncbi.nlm.nih.gov/pubmed/33499891
http://dx.doi.org/10.1186/s13011-021-00348-z
work_keys_str_mv AT maialucaso opioiduseregulationandharmsinbrazilacomprehensivenarrativeoverviewofavailabledataandindicators
AT daldeganbuenodimitri opioiduseregulationandharmsinbrazilacomprehensivenarrativeoverviewofavailabledataandindicators
AT fischerbenedikt opioiduseregulationandharmsinbrazilacomprehensivenarrativeoverviewofavailabledataandindicators